Roche to pay Nurix as much as $2.3 billion in cancer deal

Roche Holding AG agreed to pay Nurix Therapeutics Inc. as much as $2.3 billion for rights to an experimental blood-cancer ...
Investor's Business Daily on MSN

Roche inks $2.3 billion deal, sending this small biotech stock flying

Nurix Therapeutics stock bounded of its 50-day line Monday after inking a deal with Roche for its BTK-degrading drug, bex-deg ...
Fierce Biotech

Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown

Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that ...
PharmExec

Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg

Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant …

Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell ...
BioPharma Dive

Roche stakes $700M on Nurix’s protein-degrading drug

Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove ...

Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg

Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into ...

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology ...

Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted therapies and ...

F. Hoffmann-La Roche Ltd: Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg ...

Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential indicat ...